Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis-related ovarian cancers‡.

The Journal of pathology - 1 Sept 2022

Khalique Saira, Nash Sarah, Natrajan Rachael

Abstract excerpt

The ARID1A tumour suppressor protein is a component of the SWI/SNF chromatin remodelling complex, which is mutated in approximately 20% of all human cancers. ARID1A mutational status is considered to hold prognostic significance in a range of solid malignancies, yet in endometriosis-related ovarian carcinomas there has been a lack of clarity of its prognostic role. Moreover, the relationship between ARID1A status...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Endometrioid
Share to DNA-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometriosis

Share to Mutation

Share to Nuclear Proteins

Share to Ovarian Neoplasms

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 35647895
DOI: 10.1002/path.5973
PMCID: PMC9540905

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis-related ovarian cancers‡.PMID 35647895Read ↗

Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8 + TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomasSemantic proximity Read ↗

Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian CarcinomaSemantic proximity Read ↗

Prognostic role of transcription factor ARID1A in patients with endometrial cancer of no specific molecular profile (NSMP) subtype.Semantic proximity Read ↗

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.Semantic proximity Read ↗

Evaluation of ARID1A as a Potential Biomarker for Predicting Response to Immune Checkpoint Inhibitors in Patients with Endometrial CancerSemantic proximity Read ↗

Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

ARID1A gene mutation in ovarian and endometrial cancers (Review).Semantic proximity Read ↗

ARID1A: gene, protein, and function in endometrial cancer.Semantic proximity Read ↗

Diagnostic significance and prognostic role of the ARID1A gene in cancer outcomes (Review)Semantic proximity Read ↗

Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.Semantic proximity Read ↗

The impact of ARID1A mutation on molecular characteristics in colorectal cancer.Semantic proximity Read ↗

Targeting ARID1A mutations in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.